Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Teva Pharma Industries Ltd ADR (TEVAy)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Teva ADR historical data, for real-time data please try another search
7.70 0.00    0.00%
02/10 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  US8816242098 
S/N:  883035
  • Volume: 0
  • Bid/Ask: 7.55 / 7.79
  • Day's Range: 7.56 - 7.70
Teva ADR 7.70 0.00 0.00%

NYSE:TEVAy Financials

 
A brief overview of the NYSE:TEVA financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Teva over time.

For the six months ended 30 June 2016, Teva Pharmaceutical Industries Ltd (ADR) revenues decreased 1% to $9.85B. Net income applicable to common stockholders decreased 23% to $758M. Revenues reflect Generic Madicines segment decrease of 12% to $4.46B, United States segment decrease of 9% to $5.32B. Net income also reflects Other than Temporary Impairment-Securiti increase from $146M to $585M (expense).

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

TEVAy Income Statement

Gross margin TTM -
Operating margin TTM -
Net Profit margin TTM -
Return on Investment TTM -
 Total Revenue  Net Income
Period Ending: Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014
Total Revenue 4966 4982 5168 5058
Gross Profit 2902 2836 2889 2809
Operating Income 662 749 942 1112
Net Income 539 446 687 876

TEVAy Balance Sheet

Quick Ratio MRQ -
Current Ratio MRQ -
LT Debt to Equity MRQ -
Total Debt to Equity MRQ -
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014
Total Assets 50371 46951 46420 46608
Total Liabilities 27333 24315 23107 22975
Total Equity 23038 22636 23313 23633

TEVAy Cash Flow Statement

Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow  19.58%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014
Period Length: 6 Months 3 Months 12 Months 9 Months
Cash From Operating Activities 2834 1354 5127 3375
Cash From Investing Activities -5136 -219 -1450 -1103
Cash From Financing Activities 1180 93 -2375 -1782
Net Change in Cash -1158 1170 1188 435
* In Millions of (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

TEVA Comments

Write your thoughts about Teva Pharmaceutical Industries Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
TSahi Livnoni
TSahi Livnoni Apr 11, 2024 8:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
TSahi Livnoni
TSahi Livnoni Mar 23, 2024 9:54PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1% on a Friday with 9.13M volume someone is buying.
TSahi Livnoni
TSahi Livnoni Mar 13, 2024 10:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
simple story of debt reduction and value going up. revenue growth will set the pace will move up in the next 2-3 years to about 30-40$
ritchie lee
ritchie lee Jan 22, 2024 1:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
long trend starting
Ramba Łej
Kubizm Jan 22, 2024 1:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hopefully ! Ive been w8ing for it for 3 y xD
Ramba Łej
Kubizm Sep 14, 2023 10:26AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
11,40 will hold as celling or convert to floor :)?
Ramba Łej
Kubizm Aug 02, 2023 8:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
looking good on pre-market. Wonder how USA downgrade might spoil the fun here
BumHunters Archer
JohnJenga Aug 02, 2023 8:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
25 next year seems quite doable
Michael Christensen
Michael Christensen Aug 02, 2023 6:00AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Somebody know the consensus for Q2 today ?
Harel Cohen
Harel Cohen Aug 01, 2023 10:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
first real report of new CEO... it will be interesting
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email